Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 25 versus HYDRAP ES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 25 versus HYDRAP ES.
ALDORIL 25 vs HYDRAP-ES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased systemic vascular resistance and reduced blood pressure. The exact molecular mechanism involves inhibition of inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum and activation of guanylate cyclase, increasing cGMP levels.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Oral: 25-50 mg twice daily, max 200 mg/day. IV: 10-20 mg every 4-6 hours as needed.
None Documented
None Documented
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment (up to 20 hours in severe cases).
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Primarily renal (80-90% as unchanged drug); minor biliary/fecal (<10%).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination